Background: Treatment options for patients with advanced prostate cancer (PC) still remain limited
and rarely curative. The prostatic acid phosphatase (PAP) is prostate specific protein
over-expressed in more than 90% of prostate tumours. Although an FDA-approved vaccine
for the treatment of advanced prostate disease, PROVENGE® (sipuleucel-T), has been
shown to prolong survival, the precise sequence of the PAP protein responsible for
the outcome remains unknown. The aim of the study is to develop a cheaper and more
effective, Prostatic Acid Phosphatase (PAP)-based, vaccine for the treatment of advanced
prostate cancer. Our laboratory has previously shown that a 15mer PAP-derived vaccine,
when injected as a DNA vaccine, could induce PAP-specific T-cell responses and reduce
tumor growth in a syngeneic heterotopic murine prostate cancer model. We have subsequently
developed an elongated (42mer) PAP-derived peptide containing Leucine instead of an
Alanine at position 14.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
P06. Anti-cancer vaccines P06.01
Identification
Copyright
© 2018 Published by Elsevier Inc.
